AR117573A1 - Formas cristalinas de un inhibidor tlr7 / tlr8 - Google Patents
Formas cristalinas de un inhibidor tlr7 / tlr8Info
- Publication number
- AR117573A1 AR117573A1 ARP190101308A ARP190101308A AR117573A1 AR 117573 A1 AR117573 A1 AR 117573A1 AR P190101308 A ARP190101308 A AR P190101308A AR P190101308 A ARP190101308 A AR P190101308A AR 117573 A1 AR117573 A1 AR 117573A1
- Authority
- AR
- Argentina
- Prior art keywords
- tlr7
- crystalline forms
- tlr8 inhibitor
- tlr8
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018087448 | 2018-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117573A1 true AR117573A1 (es) | 2021-08-18 |
Family
ID=67145832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101308A AR117573A1 (es) | 2018-05-18 | 2019-05-16 | Formas cristalinas de un inhibidor tlr7 / tlr8 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12084460B2 (enExample) |
| EP (1) | EP3793998A1 (enExample) |
| JP (2) | JP7407740B2 (enExample) |
| KR (1) | KR20210013554A (enExample) |
| CN (1) | CN112119078A (enExample) |
| AR (1) | AR117573A1 (enExample) |
| AU (1) | AU2019268583B2 (enExample) |
| BR (1) | BR112020022738A2 (enExample) |
| CA (1) | CA3097312A1 (enExample) |
| CL (1) | CL2020002967A1 (enExample) |
| MX (2) | MX2020012259A (enExample) |
| TW (2) | TW202417000A (enExample) |
| WO (1) | WO2019220390A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019155042A1 (en) | 2018-02-12 | 2019-08-15 | F. Hoffmann-La Roche Ag | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| US12157746B2 (en) | 2018-06-05 | 2024-12-03 | Hoffmann-La Roche Inc. | Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease |
| EP3807270B1 (en) | 2018-06-12 | 2023-09-13 | F. Hoffmann-La Roche AG | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| US11952363B2 (en) | 2018-07-23 | 2024-04-09 | Hoffmann-La Roche Inc. | Piperazine compounds for the treatment of autoimmune disease |
| CN112638908A (zh) | 2018-09-04 | 2021-04-09 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的苯并噻唑类化合物 |
| WO2020048596A1 (en) | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel pyrazolopyridine compounds for the treatment of autoimmune disease |
| EP3847170B1 (en) | 2018-09-06 | 2022-06-22 | F. Hoffmann-La Roche AG | Novel cyclic amidine compounds for the treatment of autoimmune disease |
| CN114599652B (zh) | 2019-10-31 | 2024-07-12 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物 |
| EP4061816A1 (en) | 2019-11-19 | 2022-09-28 | F. Hoffmann-La Roche AG | Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
| EP4061821B1 (en) | 2019-11-20 | 2025-08-06 | F. Hoffmann-La Roche AG | Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease |
| JP2023533807A (ja) | 2020-07-14 | 2023-08-04 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物 |
| US11661431B2 (en) | 2021-04-16 | 2023-05-30 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| TW202440078A (zh) | 2021-09-10 | 2024-10-16 | 美商基利科學股份有限公司 | 噻吩并吡咯化合物 |
| PE20250401A1 (es) * | 2021-09-24 | 2025-02-11 | Hoffmann La Roche | Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades auto/inmunitarias |
| AU2023207313A1 (en) * | 2022-01-11 | 2024-06-13 | Novartis Ag | Tlr7/8-antagonist for treating sjögren's syndrome or mixed connective tissue disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11507052A (ja) | 1995-06-07 | 1999-06-22 | スージェン・インコーポレーテッド | キナゾリンおよび医薬組成物 |
| EP1940819A1 (en) | 2005-08-16 | 2008-07-09 | Memory Pharmaceuticals Corporation | Phosphodiesterase 10 inhibitors |
| EP3238722B1 (en) | 2011-01-10 | 2019-03-13 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones |
| EA039373B1 (ru) | 2012-02-08 | 2022-01-19 | Янссен Сайенсиз Айрлэнд Юси | Производные пиперидино-пиримидина для лечения вирусных инфекций |
| EA029281B1 (ru) | 2013-07-30 | 2018-03-30 | Джилид Коннектикут, Инк. | Полиморф ингибиторов syk |
| AU2016312011B2 (en) * | 2015-08-25 | 2021-02-04 | Beigene, Ltd. | Process for preparing Parp inhibitor, crystalline forms, and uses thereof |
| BR112018074911B1 (pt) * | 2016-06-30 | 2023-01-17 | Kimberly-Clark Worldwide, Inc. | Processo para fabricar um compósito de espuma e fibra, compósito de espuma e fibra, e, artigo absorvente |
| EP4059934B1 (en) * | 2016-09-09 | 2026-07-29 | Novartis AG | Compounds and compositions as inhibitors of endosomal toll-like receptors |
-
2019
- 2019-05-16 WO PCT/IB2019/054066 patent/WO2019220390A1/en not_active Ceased
- 2019-05-16 KR KR1020207032942A patent/KR20210013554A/ko not_active Ceased
- 2019-05-16 BR BR112020022738-2A patent/BR112020022738A2/pt not_active IP Right Cessation
- 2019-05-16 CN CN201980032642.0A patent/CN112119078A/zh active Pending
- 2019-05-16 EP EP19735624.9A patent/EP3793998A1/en not_active Withdrawn
- 2019-05-16 AR ARP190101308A patent/AR117573A1/es not_active Application Discontinuation
- 2019-05-16 AU AU2019268583A patent/AU2019268583B2/en not_active Ceased
- 2019-05-16 MX MX2020012259A patent/MX2020012259A/es unknown
- 2019-05-16 US US17/056,351 patent/US12084460B2/en active Active
- 2019-05-16 TW TW112150642A patent/TW202417000A/zh unknown
- 2019-05-16 JP JP2020564243A patent/JP7407740B2/ja active Active
- 2019-05-16 TW TW108116864A patent/TWI826446B/zh active
- 2019-05-16 CA CA3097312A patent/CA3097312A1/en active Pending
-
2020
- 2020-11-13 MX MX2023013584A patent/MX2023013584A/es unknown
- 2020-11-16 CL CL2020002967A patent/CL2020002967A1/es unknown
-
2023
- 2023-12-18 JP JP2023212606A patent/JP2024037930A/ja active Pending
-
2024
- 2024-08-06 US US18/795,371 patent/US20240391938A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3793998A1 (en) | 2021-03-24 |
| CN112119078A (zh) | 2020-12-22 |
| CL2020002967A1 (es) | 2021-04-30 |
| MX2020012259A (es) | 2021-01-29 |
| MX2023013584A (es) | 2023-11-30 |
| JP7407740B2 (ja) | 2024-01-04 |
| TWI826446B (zh) | 2023-12-21 |
| CA3097312A1 (en) | 2019-11-21 |
| KR20210013554A (ko) | 2021-02-04 |
| WO2019220390A1 (en) | 2019-11-21 |
| AU2019268583A1 (en) | 2020-10-29 |
| JP2024037930A (ja) | 2024-03-19 |
| US20210206783A1 (en) | 2021-07-08 |
| US20240391938A1 (en) | 2024-11-28 |
| TW202015698A (zh) | 2020-05-01 |
| TW202417000A (zh) | 2024-05-01 |
| US12084460B2 (en) | 2024-09-10 |
| AU2019268583B2 (en) | 2022-01-27 |
| BR112020022738A2 (pt) | 2021-02-02 |
| JP2021523918A (ja) | 2021-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017005790A2 (es) | Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas | |
| CL2017001617A1 (es) | Formas sólidas de un inhibidor ask1 referencia cruzada a aplicaciones relacionadas | |
| UY38448A (es) | Compuestos de azol-amida pesticidamente activos | |
| CL2015002304A1 (es) | Formas del metil {4,6-diamino-2- [1- (2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato | |
| MX2017005769A (es) | Derivados policiclicos activos como plaguicidas con sustituyentes que contienen azufre. | |
| AR095039A1 (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
| CO2019009005A2 (es) | Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas | |
| NI201200146A (es) | Inhibidores no nucleosídicos de la transcriptasa inversa | |
| AR106192A1 (es) | Formas cristalinas de un agente antiviral contra la hepatitis b | |
| AR105238A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
| MX2016013265A (es) | Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp. | |
| CL2009000275A1 (es) | Compuestos derivados de furo [3,2-c]piridina y tieno [3,2-c] piridina; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
| MX2018010025A (es) | Derivados de quinazolindion-6-carbonilo y su utilizacion como herbicidas. | |
| PE20180035A1 (es) | Tableta de ribociclib | |
| EP4603562A3 (en) | Spirobifluorene derivatives for use in electronic devices | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| MX2018009501A (es) | Forma cristalina a de agonista de tlr7, metodo de preparacion y uso de la misma. | |
| CL2019001694A1 (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos. | |
| ECSP10010598A (es) | Metodos y composiciones líquidas de limpieza | |
| NI201100069A (es) | Inhibidores de la integrasa del vih. | |
| CR20150555A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina | |
| CL2021000904A1 (es) | Método para convertir las formas e, f y g cristalinas de la sal de bis-bromuro de hidrógeno de (s)-n-((5-(etilsulfonil)piridin-2-il)metil)-7-isopropil-6-((trans-4-(trifluorometil) ciclohexil) metil)-6,7-dihidro-5h-pirrolo[3,4-b]piridin-3-carboxamida en la forma d cristalina de la sal de bis-bromuro de hidrógeno. solicitud divisional de la solicitud 190-2020 | |
| CO2017002266A2 (es) | Derivados de 5-[3-metil-2-[(4-metillsulfonilpiperazin-1-il)metil]-7-morfolinotieno [2,3-c] piridinil como inhibidores de la quinasa pi3 | |
| AR099766A1 (es) | Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos | |
| UY35036A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |